Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
This study has been completed.
Study NCT00972075   Information provided by Neurim Pharmaceuticals Ltd.

First Received on September 3, 2009.   Last Updated on September 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Non-24 Hour Sleep-Wake Disorder
Blindness
Additional conditions recognized in this trial
Parasomnias
Sleep Disorders
Sleep Disorders, Circadian Rhythm
More general conditions related to this trial
Chronobiology Disorders
Dyssomnias
Eye Diseases
Mental Disorders
Nervous System Diseases
Neurologic Manifestations
Occupational Diseases
Sensation Disorders
Signs and Symptoms
Vision Disorders
Interventions listed in this trial
melatonin (Circadin)
placebo
Additional drug interventions recognized in this trial
Melatonin
More general drug interventions related to this trial
Antioxidants
Central Nervous System Agents
Central Nervous System Depressants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Neurim Pharmaceuticals Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services